about
Cell cycle-specific function of Ikaros in human leukemiaOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer.Malaria protein kinase CK2 (PfCK2) shows novel mechanisms of regulationTenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in miceProtein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cellsRegulation of the proapoptotic functions of prostate apoptosis response-4 (Par-4) by casein kinase 2 in prostate cancer cellsIdentification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library.Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.Synthetic cytotoxicity: digenic interactions with TEL1/ATM mutations reveal sensitivity to low doses of camptothecinCK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.Emergence of protein kinase CK2 as a key target in cancer therapyProtein kinase CK2 inhibition induces cell death via early impact on mitochondrial function.Aloe-emodin, an anthraquinone, in vitro inhibits proliferation and induces apoptosis in human colon carcinoma cells.Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retinaA CK2-dependent mechanism for activation of the JAK-STAT signaling pathway.CK2 inhibitors increase the sensitivity of HSV-1 to interferon-β.Protein kinase CK2 in health and disease: CK2: a key player in cancer biologyNanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cellsApigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer.Identification of CK2 as the kinase that phosphorylates Pax3 at Ser209 in early myogenic differentiationProtein kinase CK2--a key suppressor of apoptosis.Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.The role of protein kinase CK2 in glioblastoma development.The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell linesTherapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.Specific inhibition of CK2α from an anchor outside the active siteThe tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies.Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.CK2 kinase activity but not its binding to CK2 promoter regions is implicated in the regulation of CK2α and CK2β gene expressions.Stimulation of CK2-dependent Grp94 phosphorylation by the nuclear localization signal peptide.Casein kinase 2 regulates the mRNA-destabilizing activity of tristetraprolin.Phosphorylation of the HuR ligand APRIL by casein kinase 2 regulates CD83 expression.CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.Modulation of protein kinase CK2 activity by fragments of CFTR encompassing F508 may reflect functional links with cystic fibrosis pathogenesisInhibition of casein kinase 2 modulates XBP1-GRP78 arm of unfolded protein responses in cultured glial cells.
P2860
Q24298114-31CEA973-CEF8-428B-902B-BD0FD7A98132Q27332192-E930A593-4441-4301-B33A-AA9993C53856Q27973595-A1C9F60F-881C-47EA-94A6-73433E0069EEQ28543800-1B18ED54-43EF-45C4-9755-5B8B82630A2FQ28574087-4863C05F-A303-4333-B955-B9CC569B9543Q28575412-7FBBD2DD-12F8-4969-B366-69F08DE6C50EQ33440068-308990BD-CD2A-41F3-92F8-C7380E7D340FQ33445369-5726215E-F73E-4EF5-9602-0BB2D9F23F49Q33779587-9A2DF8D1-B061-4D84-B8A1-7172DCBB9927Q33817704-C0A06520-380B-4C0E-81C4-74FC55871115Q34020978-7FAF3E3A-771E-4C93-AFDB-F92D16E8BAA5Q34034867-10799052-9C80-46D8-AF48-179E95615799Q34046848-407B2AF0-D7FF-44BA-BBA1-96F88A088360Q34353356-2CB411A7-8CBB-4E07-8D34-482ECA845B4CQ34410937-8AAC9D04-E094-4726-BFA4-3BE968D507F7Q35088245-1BD2229B-BC5F-48FB-B9DF-A911CE57D16FQ35114492-55C7FADE-308D-4504-BC16-F259415AA50BQ35175764-0A60B7AC-AEA0-4F30-9AEA-2508E4FB242FQ35270830-5FF900ED-421F-45D7-B6E4-80659D5071A0Q35577635-1E6E0265-28C2-4748-9804-2E7652429B3FQ36267629-AE86C9D9-7D62-4FBA-ABAE-708C5D9C2FCCQ36406554-35054610-D53F-4ABC-9431-5623D65C17D4Q36994133-CD2F034C-92F1-410E-A38D-31C4B6610688Q37121790-81E91E9B-53A7-434A-8234-4288D6179DA0Q37466127-412F390B-4D24-46D7-9D87-DB5FE38A913EQ37487082-7C2CA10B-AD5E-470F-88AF-98E54B73AD44Q37599620-A8047D9E-C11F-4381-B9B2-334B35967B06Q38709045-A9418162-5B6E-47AD-AAC3-350B562BEB9FQ38740809-5B8CBDE4-5C02-41F2-91B8-8D35400F4F8FQ38815725-2A4661F9-3943-4D86-B044-A2BB5E8900BCQ38905460-C02D6BF6-AEDE-4E8E-9FE1-9BE88BBABCDFQ38964075-3DCF8DF1-5B24-4077-9E62-C40716E598D0Q39107310-9728860C-1C58-4B94-9DA2-A4F9994A92CDQ39510526-9289FDFF-1F0F-4D2C-AEE3-945FB78FC638Q39555596-EEC3AD1F-806D-4F6F-9EB4-C758CB2E6581Q39897656-44ADD7DA-895E-4784-80D7-CCD53D1CF851Q40056601-819E02CE-F197-4748-AB55-02092AC32127Q40135888-7ECCEBE1-9B3F-4F4B-8BD6-C9FD2212A62FQ41788874-2076AA96-0A94-41CD-8E2B-7FB716F23463Q42020600-DB246975-682C-4E88-BAA2-1E2A81D0AA19
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Targeting CK2 for cancer therapy.
@ast
Targeting CK2 for cancer therapy.
@en
type
label
Targeting CK2 for cancer therapy.
@ast
Targeting CK2 for cancer therapy.
@en
prefLabel
Targeting CK2 for cancer therapy.
@ast
Targeting CK2 for cancer therapy.
@en
P2093
P1433
P1476
Targeting CK2 for cancer therapy.
@en
P2093
Gretchen Unger
Guixia Wang
Joel Slaton
Kashif A Ahmad
Khalil Ahmed
P304
P356
10.1097/00001813-200511000-00001
P577
2005-11-01T00:00:00Z